High-dose benzodiazepine dependence: a qualitative study of patients’ perception on cessation and withdrawal
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Benzodiazepine withdrawal syndrome has been reported following attempts to withdraw even from low or therapeutic doses and has been compared to barbiturate and alcohol withdrawal. This experience is known to deter patients from future cessation attempts. Research on other psychotropic substances shows that the reasons and motivations for withdrawal attempts - as well as the experiences surrounding those attempts - at least partially predict future efforts at discontinuation as well as relapse. We therefore aimed to qualitatively explore what motivates patients to discontinue this medication as well as to examine their experiences surrounding previous and current withdrawal attempts and treatment interventions in order to positively influence future help-seeking behavior and compliance. METHODS: To understand these patients better, we conducted a series of 41 unstructured, narrative, in-depth interviews among adult Swiss patients with a long-term dependent use of benzodiazepines in doses equivalent to more than 40 mg diazepam per day and/or otherwise problematic use (mixing benzodiazepines, escalating dosage, recreational use or illegal purchase). Mayring's qualitative content analysis was used to evaluate findings. RESULTS: These high-dose benzodiazepine-dependent patients decision to change consumption patterns were affected by health concerns, the feeling of being addicted and social factors. Discontinuation attempts were frequent and not very successful with fast relapse. Withdrawal was perceived to be a difficult, complicated, and highly unpredictable process. The first attempt at withdrawal occurred at home and typically felt better than at the clinic. Inpatient treatment was believed to be more effective with long term treatment (approaches) than short term. Patients preferred gradual reduction of usage to abrupt cessation (and had experienced both). While no clear preferences for withdrawal were found for benzodiazepines with specific pharmacokinetic properties, participants frequently based their decision to participate in treatment on the availability of their preferred brand name and furthermore discarding equivalent dosage rationales. CONCLUSIONS: Our findings provide greater understanding of the factors that motivate high-dose benzodiazepine-dependent individuals to stop taking these medications, and how they experience withdrawal and treatment strategies. They underscore how patients' perceptions of treatment approaches contribute to compliant or non-compliant behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, X., Nonnemaker, J., Sherrill, B., Gilsenan, A. W., Coste, F., & West, R. (2009) · Addictive Behaviors · doi:10.1016/j.addbeh.2008.11.013 · Cited by 508
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 3×
“Benzodiazepine withdrawal syndrome has been reported following attempts to withdraw even from low or therapeutic doses [12,17], and has been compared to barbiturate and alcohol withdrawal [18-20].”
BackgroundResultBenzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318 · cited 1×
“Accordingly, some researchers have called for investigation of long-term and/or high-dose users in relation to evaluating discontinuation of treatment [15,24,25].”
BackgroundCognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312 · cited 1×
“Adverse effects most notably include cognitive and psychomotor impairments, as well as dependence after continuous and/or long-term use [4-6].”
BackgroundDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210 · cited 1×
“They are most commonly used to treat symptoms of anxiety and insomnia [1-3].”
BackgroundProtracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 1×
“More specifically, participants said that they had experienced chills, weakness, headache, muscle pains, abdominal pain, nausea, vomiting, diarrhea, tachycardia, dizziness, vision disorders, irritability, nervousness, restlessness, difficulties sleeping, symptoms of depression and anxiety, tickling sensations, dissoci…”
ResultPetitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132 · cited 1×
“6% of patients with longterm use of BZDs (n = 25 354) received prescriptions exceeding recommended dosage by at least two times [10].”
BackgroundBenzodiazepine withdrawal phenomena
Hallstrom, C., & Lader, M. (2017) · International Pharmacopsychiatry · doi:10.1159/000468500 · Cited by 132
Chronic benzodiazepine usage and withdrawal in insomnia patients
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.003 · Cited by 94 · cited 1×
“Benzodiazepine withdrawal syndrome has been reported following attempts to withdraw even from low or therapeutic doses [12,17], and has been compared to barbiturate and alcohol withdrawal [18-20].”
Result
Cited by
Discontinuing Psychiatric Medications: A Survey of Long-Term Users
Ostrow, L., Jessell, L., Hurd, M., Darrow, S. M., & Cohen, D. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700070 · Cited by 62
Benzodiazepine Withdrawal: Clinical Aspects
Wright, S. L. (2020) · The Benzodiazepines Crisis · doi:10.1093/med/9780197517277.003.0008 · Cited by 7
Pharmacological principles for safe benzodiazepine and Z-drug dose reduction
Horowitz, M., Lamberson, N., Brandt, J., Framer, A., Shapiro, B., Sørensen, A., Cadogan, C., Ritvo, A., & Taylor, D. (2026) · Psychological Medicine · doi:10.1017/s0033291726104887
“Patients also experience the withdrawal process as a difficult, complicated, and highly unpredictable process (Liebrenz, Gehring, Buadze, & Caflisch, 2015), some reporting that benzodiazepines are harder to discontinue than opioids because of the withdrawal symptoms (Liebrenz et al., 2015).”
Metadata
- Authors
- Liebrenz, M., Gehring, M.-T., Buadze, A., & Caflisch, C.
- Venue
- BMC Psychiatry
- Published
- 2015-05-13
- Volume
- 15
- Issue
- 1
- Pages
- 116-116
- ISSN
- 1471-244X (ISSN-L)
- OpenAlex
- W1552653847
- Cited by
- 41
- References
- 14
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose benzodiazepine dependence: a qualitative study of patients’ perception on cessation and withdrawal. https://app.cochat.ai/papers/10.1186/s12888-015-0493-y
- The paper
- Liebrenz, M., Gehring, M.-T., Buadze, A., & Caflisch, C. (2015). High-dose benzodiazepine dependence: a qualitative study of patients’ perception on cessation and withdrawal. BMC Psychiatry. https://doi.org/10.1186/s12888-015-0493-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.